BusinessKorea | Korea's Premier Business Portal

Wednesday, November 22, 2017

The authorization of Ontruzant in Europe made Samsung Bioepis the company with World’s largest number of biosimilars.
Company with Largest Number of Biosimilars
21 November 2017 - 12:15pm
'Ontruzant' (ingredient name: trastuzumab, project name: SB3), an anti-cancer drug developed by Samsung Bioepis,... more
Korean large businesses spent 40.78 trillion won (US$36.47 billion) on R&D activity, accounting for 77.8 percent of the total private R&D investments of 52.35 trillion won (US$46.82 billion).
Amid Lacking in Qualitative Results
15 November 2017 - 10:45am
According to the a survey titled “2016 R&D activity” of 57,581 institutions in South Korea, such as public research... more
Now is the time for the Moon Jae-in administration to stop reiterating dialogue with Pyongyang and to seek for the best way for tactical nuclear weapon redeployment and nuclear armament.
Publisher Note
12 September 2017 - 1:30pm
South Korea has found itself at a crossroads yet again. Those threatening its economy this time include Kim Jong-un’s... more

Copyright 2013 BusinessKorea Co., Ltd.
301 Samdo Building, 12-1
Yeoido-dong, Yeongdeungpo-gu
Seoul, Korea 150-010
Tel: +82-2-578-3220
Fax: +82-2-578-3224
Email: contact@businesskorea.co.kr

 
 

Web design by: